Pancreatic Disorders News

The FDA has granted orphan drug designation to Ionis Pharmaceuticals’ olezarsen, an investigational ligand-conjugated antisense drug for the treatment of familial chylomicronemia syndrome, according to a company release.

Adults with type 2 diabetes who use GLP-1 receptor agonists do not have an increased short-term risk for pancreatic cancer, according to findings published in JAMA Network Open.

Upfront endoscopic necrosectomy performed at the index intervention resulted in fewer reinterventions compared with a step-up treatment approach among patients with infected necrotizing pancreatitis and fully encapsulated collections.

Throughout 2023, gastroenterology societies made several significant clinical practice updates to guide diagnosis, management and treatment of various GI disorders such as celiac disease, inflammatory bowel disease and acute liver failure.

Laparoscopic pancreaticoduodenectomy had similar short-term outcomes compared with open surgery among patients with pancreatic ductal adenocarcinoma, according to study results published in JAMA Surgery.

The placement of a coaxial double pigtail plastic stent within a lumen-apposing metal stent for drainage of pancreatic fluid collection did not improve clinical success or safety outcomes, according to results from a single-center study.

Use of glucagon-like peptide 1 agonists for weight loss compared with bupropion-naltrexone was associated with an increased risk for pancreatitis, gastroparesis and bowel obstruction but not biliary disease, researchers reported in JAMA.

Citing an “urgent need” for best practice updates to improve awareness and treatment for exocrine pancreatic insufficiency, the AGA has published new guidance to aid clinicians in evaluation and management of the disease.

Elevated serum triglyceride levels were associated with severity of acute pancreatitis and risk for related complications, including organ failure, among patients with nonalcoholic fatty liver disease, according to data.

From pancreatitis complications to the impact of long COVID, FDA updates to gender disparity in pancreatic cancer, Healio has been at the forefront of coverage for pancreatic disorders in 2023. What have you missed this year?